001     144225
005     20240229112619.0
024 7 _ |a 10.1093/carcin/bgy161
|2 doi
024 7 _ |a pmid:30753335
|2 pmid
024 7 _ |a 0143-3334
|2 ISSN
024 7 _ |a 1460-2180
|2 ISSN
024 7 _ |a altmetric:55406703
|2 altmetric
037 _ _ |a DKFZ-2019-01745
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Griessinger, Christoph M
|b 0
245 _ _ |a The administration route of tumor-antigen-specific T-helper cells differentially modulates the tumor microenvironment and senescence.
260 _ _ |a Oxford
|c 2019
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1562576323_9582
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cancer treatment with adoptively transferred tumor-associated antigen-specific CD4+ T-helper cells is a promising immunotherapeutic approach. In the pancreatic cancer model RIP-Tag2, the intraperitoneal (i.p.) application of Tag-specific TH1 cells exhibited a profound antitumoral efficiency. We investigated, whether an intravenous (i.v.) application of Tag-TH1 cells induces an equivalent therapeutic effect. Adoptively transferred fluorescent Tag-TH1 cells revealed a pronounced homing to the tumors after either i.p. or i.v. transfer, and both routes induced an almost equivalent therapeutic effect as demonstrated by magnetic resonance imaging, blood glucose level course and histology. The i.v. administration of Tag-TH1 cells induced p16INK4-positive/Ki67-negative tumor senescence more efficiently than i.p. administration. Both routes replenish host CD4+ T cells by transferred T cells and recruitment of B and dendritic cells to the tumors while reducing CD8+ T cells and depleting macrophages. Both administration routes efficiently induced a similar antitumoral efficiency despite the pronounced senescence induction after i.v. administration. Thus, a combinatory i.v./i.p. injection of therapeutic cells might overcome limitations of the individual routes and improve therapeutic efficacy in solid tumors.
536 _ _ |a 319H - Addenda (POF3-319H)
|0 G:(DE-HGF)POF3-319H
|c POF3-319H
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Schmid, Andreas M
|b 1
700 1 _ |a Sonanini, Dominik
|b 2
700 1 _ |a Schörg, Barbara F
|b 3
700 1 _ |a Jarboui, Mohamed Ali
|b 4
700 1 _ |a Bukala, Daniel
|b 5
700 1 _ |a Mucha, Natalie
|b 6
700 1 _ |a Fehrenbacher, Birgit
|b 7
700 1 _ |a Steinhilber, Julia
|b 8
700 1 _ |a Martella, Manuela
|b 9
700 1 _ |a Kohlhofer, Ursula
|b 10
700 1 _ |a Schaller, Martin
|b 11
700 1 _ |a Zender, Lars
|0 P:(DE-He78)1ba2900406378e069d32db376c7818db
|b 12
|u dkfz
700 1 _ |a Rammensee, Hans-Georg
|0 P:(DE-He78)58a4f09f3edfdce451d520a5be7979fc
|b 13
|u dkfz
700 1 _ |a Quintanilla-Martinez, Leticia
|b 14
700 1 _ |a Röcken, Martin
|b 15
700 1 _ |a Kneilling, Manfred
|b 16
700 1 _ |a Pichler, Bernd J
|b 17
773 _ _ |a 10.1093/carcin/bgy161
|g Vol. 40, no. 2, p. 289 - 302
|0 PERI:(DE-600)1474206-8
|n 2
|p 289 - 302
|t Carcinogenesis
|v 40
|y 2019
|x 1460-2180
909 C O |o oai:inrepo02.dkfz.de:144225
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)1ba2900406378e069d32db376c7818db
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)58a4f09f3edfdce451d520a5be7979fc
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-319H
|2 G:(DE-HGF)POF3-300
|v Addenda
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CARCINOGENESIS : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CARCINOGENESIS : 2017
920 1 _ |0 I:(DE-He78)V076-20160331
|k V076
|l Translationale Gastrointestinale Onkologie
|x 0
920 1 _ |0 I:(DE-He78)L801-20160331
|k L801
|l DKTK Tübingen
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)V076-20160331
980 _ _ |a I:(DE-He78)L801-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21